Table 2. Antibody sequence analysis for the V gene usage and CDR3 sequence.
| mAb | Donor | Heavy chain | Light chain | ||||
|---|---|---|---|---|---|---|---|
| V gene % identity |
CDR3 AA length | CDR3 AA sequence | V gene % identity |
CDR3 AA length | CDR3 AA sequence | ||
| 2N6 | 1 | IGHV4-34*02 78% |
8.7.14 | CAAPRRVDGYNLLDSW | IGLV1-40*01 94% |
9.3.12 | CQSFDNSRTAFYIF |
| 3M3 | 2 | IGHV4-34*08 91% |
8.7.16 | CSRGVADRISSSWHYDLW | IGLV3-21*02 87% |
6.3.11 | CQVWDMENDHPVF |
| 6F18 | 1 | IGHV6-1*01 91% |
10.9.17 | CARSQDDSSGYHEDFFDFW | IGKV4-1*01 96% |
12.3.9 | CQQYYRMPYTF |
| 17E10 | 2 | IGHV3-15*01 87% |
8.10.8 | CSVLYSLQHW | IGLV7-46*01 90% |
9.3.9 | CLLSYNNMLVF |
Analysis was carried out using IMGT/VQUEST [32]. The predicted V gene usage is displayed for both heavy chain and light chain, along with the CDR3 sequence and length based on the amino acid (AA) sequence.